A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

September 29, 2021

Study Completion Date

September 29, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

.[14C]-SKI-O-703

Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc., Madison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oscotec Inc.

INDUSTRY

NCT05042986 - A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects | Biotech Hunter | Biotech Hunter